He responded to a request from Senator Hawley that highlighted new research on the dangers of mifepristone.
Food and Drug Administration Commissioner Marty Makary has committed his agency to conduct a full review of mifepristone. Originally, the new commissioner had not intended to take action to reconsider the risks posed by the abortion drug. After receiving a letter from Senator Josh Hawley of Missouri pointing out research on the potential harms, the commissioner changed his mind.
Health and Human Services Secretary Robert F. Kennedy, Jr. had affirmed before a Senate committee that he would ask the FDA commissioner to do a complete review as well.
Secretary Kennedy called the report that showed 11 percent of women who take mifepristone experience sepsis, infection, hemorrhaging, or other adverse health events in the following 45 days “alarming.” He said, “At the very least, the label should be changed.”
The abortion drug study shows that the threat of serious complications is 22 times higher than either the FDA or the manufacturer has acknowledged.
As the Lord Leads, Pray with Us…
- For Commissioner Makary to be discerning as he oversees the review of the health risks of the abortion drug.
- For wisdom for Secretary Kennedy as he heads the Department of Health and Human Services.
Sources: Life News, Washington Examiner, The Hill
